Colgate-Palmolive (NYSE: CL) insider transactions
In the twelve months to 10 November 2026, executives and directors of Colgate-Palmolive reported 19 open-market sales of 680,830 shares ($63.8m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 5 November 2026 | Norrington Lorrie M | Director | Option exercise | +4,170 | $71.56 | 47,553 | Form 4 |
| 5 November 2026 | Norrington Lorrie M | Director | Open-market sale | −4,170 | $99.31 | 43,383 | Form 4 |
| 5 November 2026 | Wallace Noel R. | Chairman, President & CEO | Open-market sale | −20,000 | $100.26 | 359,700 | Form 4 |
| 4 November 2026 | Hazlin John | Chief Growth Officer | Option exercise | +23,376 | $77.04 | 50,397 | Form 4 |
| 4 November 2026 | Hazlin John | Chief Growth Officer | Open-market sale | −23,376 | $99.15 | 27,021 | Form 4 |
| 4 November 2026 | Tsourapas Panagiotis | COO, CD, EMEA, APac, Skin | Option exercise | +19,938 | $76.41 | 29,049 | Form 4 |
| 4 November 2026 | Tsourapas Panagiotis | COO, CD, EMEA, APac, Skin | Open-market sale | −19,938 | $98.74 | 9,111 | Form 4 |
| 1 October 2026 | Bilbrey John P | Director | Grant or award | +271 | $87.42 | 40,725 | Form 4 |
| 1 October 2026 | Newman Brian | Director | Grant or award | +214 | $87.42 | 8,058 | Form 4 |
| 1 October 2026 | Norrington Lorrie M | Director | Grant or award | +300 | $87.42 | 43,310 | Form 4 |
| 16 September 2026 | Malcolm Gregory | EVP and Controller | Grant or award | +1,081 | — | 14,162 | Form 4 |
| 16 September 2026 | Fishbone Betsy | CLO and Secretary | Grant or award | +2,207 | — | 16,050 | Form 4 |
| 16 September 2026 | Massey Sally | Chief People Officer | Grant or award | +3,333 | — | 15,397 | Form 4 |
| 16 September 2026 | Hazlin John | Chief Growth Officer | Grant or award | +3,908 | — | 27,021 | Form 4 |
| 16 September 2026 | Sutula Stanley J Iii | Chief Financial Officer | Grant or award | +8,045 | — | 79,029 | Form 4 |
| 16 September 2026 | Tsourapas Panagiotis | COO, CD, EMEA, APac, Skin | Grant or award | +4,597 | — | 11,447 | Form 4 |
| 16 September 2026 | Grant Shane | COO, Americas | Grant or award | +7,355 | — | 79,503 | Form 4 |
| 16 September 2026 | Wallace Noel R. | Chairman, President & CEO | Grant or award | +29,649 | — | 379,700 | Form 4 |
| 13 September 2026 | Fishbone Betsy | CLO and Secretary | Shares withheld for tax | −472 | $86.80 | 13,843 | Form 4 |
| 13 September 2026 | Hazlin John | Chief Growth Officer | Shares withheld for tax | −499 | $86.80 | 23,113 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Colgate-Palmolive page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.